ADC Therapeutics Ltd ADCT
NYSE · United States · Health Technology
$1.08-0.14 (-11.48%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m. ET.
On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The central fair value estimate for ADC Therapeutics has been cut from US$5.00 to about US$3.33, which marks a sizeable reset in modeled upside for the stock. Analysts are linking these lower targets to mixed LOTIS-5 outcomes, a more cautious view on Zynlonta’s growth potential, and a wider debate on how much LOTIS-7 can offset current concerns. As you read on, you will see how this evolving narrative might shape expectations and what to watch next if you follow ADC Therapeutics. Analyst...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.